Literature DB >> 10712353

A novel alveolar type I cell-specific biochemical marker of human acute lung injury.

V Newman1, R F Gonzalez, M A Matthay, L G Dobbs.   

Abstract

Currently there is no recognized biochemical or molecular marker for human parenchymal lung injury analogous to markers for acute myocardial injury. Injury to the alveolar epithelial barrier is of central importance in the pathogenesis of and recovery from acute lung injury. In animal models, an alveolar type I cell-specific protein, RTI(40), has been shown to be an accurate marker of alveolar epithelial damage. We now report that HTI(56), a novel apical plasma membrane protein specific to the human type I cell, is a biochemical marker for lung injury. Using a sensitive, quantitative, light-based ELISA, we measured HTI(56) in pulmonary edema fluid from 15 patients with a clinical diagnosis of acute lung injury and 12 control patients with hydrostatic (cardiogenic) pulmonary edema. HTI(56) was also measured in plasma from these two groups and from 11 normal volunteers. The amount of HTI(56) was 4. 3-fold higher (p < 0.0001) in alveolar edema fluid and 1.4-fold higher (p < 0.05) in plasma from the patients with acute lung injury, compared with patients with hydrostatic pulmonary edema. To our knowledge, this study is the first to utilize a specific marker of alveolar epithelial damage in human disease and demonstrates the feasibility of using a blood test to detect lung parenchymal damage.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10712353     DOI: 10.1164/ajrccm.161.3.9901042

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  8 in total

1.  HTII-280, a biomarker specific to the apical plasma membrane of human lung alveolar type II cells.

Authors:  Robert F Gonzalez; Lennell Allen; Linda Gonzales; Philip L Ballard; Leland G Dobbs
Journal:  J Histochem Cytochem       Date:  2010-06-21       Impact factor: 2.479

Review 2.  The receptor for advanced glycation end products and acute lung injury/acute respiratory distress syndrome.

Authors:  Weidun Alan Guo; Paul R Knight; Krishnan Raghavendran
Journal:  Intensive Care Med       Date:  2012-07-10       Impact factor: 17.440

3.  In vitro transdifferentiation of human fetal type II cells toward a type I-like cell.

Authors:  Cherie D Foster; Linda S Varghese; Rachel B Skalina; Linda W Gonzales; Susan H Guttentag
Journal:  Pediatr Res       Date:  2007-04       Impact factor: 3.756

4.  Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury.

Authors:  Tokujiro Uchida; Madoka Shirasawa; Lorraine B Ware; Katsuo Kojima; Yutaka Hata; Koshi Makita; Gabe Mednick; Zachary A Matthay; Michael A Matthay
Journal:  Am J Respir Crit Care Med       Date:  2006-02-02       Impact factor: 21.405

5.  SP-D, KL-6, and HTI-56 levels in children with mycoplasma pneumoniae pneumonia.

Authors:  Lin-Hua Shu; Quan Lu; Li-Ying Han; Guang-Hui Dong
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

6.  Alveolar type I cells protect rat lung epithelium from oxidative injury.

Authors:  Jiwang Chen; Zhongming Chen; Narendranath Reddy Chintagari; Manoj Bhaskaran; Nili Jin; Telugu Narasaraju; Lin Liu
Journal:  J Physiol       Date:  2006-05-01       Impact factor: 5.182

Review 7.  A Pathophysiologic Approach to Biomarkers in Acute Respiratory Distress Syndrome.

Authors:  Raiko Blondonnet; Jean-Michel Constantin; Vincent Sapin; Matthieu Jabaudon
Journal:  Dis Markers       Date:  2016-02-11       Impact factor: 3.434

Review 8.  A systematic review of diagnostic methods to differentiate acute lung injury/acute respiratory distress syndrome from cardiogenic pulmonary edema.

Authors:  Kosaku Komiya; Tomohiro Akaba; Yuji Kozaki; Jun-Ichi Kadota; Bruce K Rubin
Journal:  Crit Care       Date:  2017-08-25       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.